ArticleOphthalmology. Retina2025
Associations between Androgen Exposure, Polycystic Ovary Syndrome, and Transmasculine Individuals with Central Serous Chorioretinopathy.
Article in Ophthalmology. Retina, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Choroidal vascularization in polycystic ovary syndrome: an optical coherence tomography study.International ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThe prevalence of central serous chorioretinopathy (CSCR) among transmasculine, polycystic ovary syndrome (PCOS), and androgen-exposed patients remains largely unexplored. Although these groups involve patients with elevated testosterone levels, previous literature is inconclusive on the influence of testosterone on CSCR. This study aimed to determine the relationship between CSCR and cohorts with exogenous androgen exposure, female-to-male (FTM) transgender individuals, and those diagnosed with PCOS.
designCross sectional study. SUBJECTS: Patients with CSCR, receiving exogenous androgens, FTM transgender individuals (defined as gender identity disorder [GID], endocrine disorder not otherwise specified, sex-discordant hormone therapy, and FTM surgery), and patients with PCOS.
methodsAn electronic health records platform of >100 million patients was examined for this study. Patients were identified through 10th revision of the International Classification of Diseases and procedural codes. Patients with prior steroid prescriptions, anxiety disorders, and fluticasone use were excluded. Prevalence and prevalence odds ratios (ORs) of comorbid CSCR were calculated using RStudio and 95% confidence intervals (CIs) were calculated.
main outcome measuresPrevalence, prevalence ORs, and 95% CIs of CSCR.
resultsAmong 21 056 patients with CSCR, the mean age was 61 years (standard deviation ± 15), with 67.95% being male. The prevalence of CSCR was highest among those receiving exogenous androgen therapy (24.13 per 1000 patients with CSCR; OR: 5.84, 95% CI: 5.35-6.37). The FTM surgery (OR: 3.04) and sex-discordant hormone therapy (OR: 5.32) cohorts also showed significant associations with CSCR (P < 0.05). Patients with PCOS had a more limited but still significant association (OR: 1.23, 95% CI: 1.013-1.49). Gender identity disorder did not show a significant relationship with CSCR (P > 0.05).
conclusionsThis study, which investigated the associations between FTM transgender, patients with PCOS, and CSCR demonstrates that conditions linked with elevated androgens are associated with higher odds of CSCR. These findings emphasize the value of ophthalmic screenings in these populations, particularly within the transgender health care community. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.